Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 11/20 | 0.54 |
| ▸ | CNR1 | P21554 | 5/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1983540 | 0.91 | CNR2 (0.54) | CNR2CNR1LMNA | |
| SCHEMBL1986215 | 0.89 | CNR2 (0.54) | CNR2CNR1 | |
| SCHEMBL6428002 | 0.87 | CNR2 (0.48) | CNR2CNR1LMNA | |
| SCHEMBL1986564 | 0.84 | CNR2 (0.54) | CNR2CNR1LMNA | |
| SCHEMBL1985122 | 0.83 | CYP1A2 (0.47) | CNR1 | |
| SCHEMBL1985351 | 0.83 | CNR2 (0.53) | CNR2CNR1LMNA | |
| SCHEMBL5524962 | 0.83 | CNR2 (0.58) | CNR2CNR1 | |
| SCHEMBL14510326 | 0.83 | CNR2 (0.58) | CNR2CNR1 | |
| SCHEMBL30571219 | 0.82 | CNR2 (0.76) | CNR2CNR1 | |
| SCHEMBL924033 | 0.82 | CNR2 (0.76) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966194-A2 | SUBSTITUTED 5-HETEROARYL-1-PHENYL-PYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-10 | — | — | EP | claimed |
| WO-2007061948-A2 | SUBSTITUTED 5-HETEROARYL-1-PHENYL-PYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-05-31 | — | — | WO | claimed |
| US-20070117858-A1 | SUBSTITUTED 5-HETEROARYL-1-PHENYL-PYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-05-24 | — | — | US | claimed |
| EP-1602656-A1 | PYRAZOLE DERIVATIVES HAVING AFFINITY FOR CB1 AND/OR CB2 RECEPTORS | NEUROSCIENZE PHARMANESS S.C. a R.L. (IT) | 2005-12-07 | — | — | EP | claimed |
| US-20050261281-A1 | Pharmaceutical compounds | MIDCAP FUNDING III, LLC | 2005-11-24 | — | — | US | claimed |
| US-8227620-B2 | Pharmaceutical compounds | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2012-07-24 | — | — | US | disclosed |
| EP-1602656-B1 | PYRAZOLE DERIVATIVES HAVING AFFINITY FOR CB1 AND/OR CB2 RECEPTORS | NEUROSCIENZE PHARMANESS S C A R L (IT) | 2011-06-29 | — | — | EP | disclosed |
| US-20100105896-A1 | PHARMACEUTICAL COMPOUNDS | Neuroscienze Pharmaness S.C.a.R.I. (IT) | 2010-04-29 | — | — | US | disclosed |
| US-7659407-B2 | pyrazole derivatives having affinity for cannabinoidergic CB1 and/or CB2 receptors; immune disorders, osteoporosis, renal ischemia, inflammation,transplant rejection; 5-(5-Chloro-thiofen-2-yl)-1-(4-methoxy-phenyl)-4-methyl-1H-pyrazol-3-carboxylic acid | Neuroscienze Pharmaness S.C.a.R.I. (IT) | 2010-02-09 | — | — | US | disclosed |
| EP-1966194-A2 | SUBSTITUTED 5-HETEROARYL-1-PHENYL-PYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007061948-A2 | SUBSTITUTED 5-HETEROARYL-1-PHENYL-PYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-05-31 | — | — | WO | disclosed |
| US-20070117858-A1 | SUBSTITUTED 5-HETEROARYL-1-PHENYL-PYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-05-24 | — | — | US | disclosed |
| EP-1602656-A1 | PYRAZOLE DERIVATIVES HAVING AFFINITY FOR CB1 AND/OR CB2 RECEPTORS | NEUROSCIENZE PHARMANESS S.C. a R.L. (IT) | 2005-12-07 | — | — | EP | disclosed |
| US-20050261281-A1 | Pharmaceutical compounds | MIDCAP FUNDING III, LLC | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105896-A1 | PHARMACEUTICAL COMPOUNDS | CNR1, CNR2, OPRD1 | CNR2 2/4885CNR1 1/4885LMNA 4227/4885 |
| US-20050261281-A1 | Pharmaceutical compounds | CNR1, CNR2, OPRD1 | CNR2 2/4885CNR1 1/4885LMNA 3062/4885 |
| US-20070117858-A1 | SUBSTITUTED 5-HETEROARYL-1-PHENYL-PYRAZOLE CANNABINOID MODULATORS | CNR1, CNR2, GPR18 | CNR2 2/4885CNR1 1/4885LMNA 4037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.